Form 4 for ALLO Allogene Therapeutics, Inc.

Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-16 · accession 0001737287-24-000042 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-05-20	2024-05-16	ALLO	Belldegrun Arie	Dir	P - Purchase	$2.90	+1.72M	1.72M	New	+$5.00M
I	2024-05-20	2024-05-16	ALLO	Belldegrun Arie	Dir	A - Grant	$2.90	+344.8K	539.9K	+177%	+$1.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-05-16	P	A	1,724,137	$2.90	1,724,137	I See footnote	—	—	(F3) Consists of 1,720,172 shares of common stock acquired by Vida Ventures III, L.P. and 3,965 shares of common stock acquired by Vida Ventures III A, L.P. from Goldman Sachs (the Underwriter) in a registered direct offering. (F4) The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
2	Common	Common Stock	2024-05-16	A	A	344,828	$2.90	539,867	I See footnote	—	—	(F1) These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering. (F2) The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.